Overview
Here are Top Health stories for the day
Online courses to doctors even if mandated by Medical Council should be taxed under GST: AAR
Delhi: Medical student sexually assaulted by man who befriended her on dating app; accused nabbed
Expedite NEET SS 2021 Counselling: Doctors Write To Health Minister
Upset over the continuous delay in the NEET-SS 2021 counselling, the doctors under the umbrella of the Federation of All India Medical Association (FAIMA) has recently written to the Union Health Minister Mansukh Mandaviya seeking his interference for expediting the counselling process.
Expressing its concern over the anguish and unrest among the super-specialists, the association has dropped a hint of agitation in the letter if the problem doesn't get sorted soon.
For more details, check out the full story on the link below:
Expedite NEET SS 2021 Counselling: Doctors Write To Health Minister
8692 MBBS, 2375 BDS, 374 BSc nursing seats up for grabs in MCC round 2 NEET counselling
A total of 11,441 including 8692 MBBS, 2375 BDS, 374 BSc Nursing seats are up for grabs in Round 2 NEET counselling being conducted by the Medical Counselling Committee (MCC) under DGHS for this academic year's UG admissions. In addition, 4464 MBBS, BDS and BSc Nursing seats are available in the virtual vacancy category.
The aggregate is derived from the recent seat matrix published by the MCC on its official website indicating the number of MBBS, BDS and BSc Nursing seats available across medical, dental and nursing colleges in the country with respect to the second round of NEET AIQ Counselling 2021. The seat matrix includes the new seats approved or added by the institutions.
For more information, check out the full story on the link below:
8692 MBBS, 2375 BDS, 374 BSc Nursing Seats Up For Grabs In MCC Round 2 NEET Counselling
Serdia Pharma Gets CDSCO Nod For Anti-Diabetic FDC Of Extended-Release Gliclazide 60mg Plus Metformin 1000mg Tablet
In a significant development, Serdia® Pharmaceuticals (India) Pvt. Ltd. has got approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market an anti-diabetic fixed-dose combination uncoated bilayer tablet comprising Gliclazide 60mg (as extended-release) plus Metformin Hydrochloride IP 1000mg (as extended-release) tablet.
Gliclazide plus Metformin is a combination of two antidiabetic medicines, used in the treatment of type 2 diabetes mellitus (T2DM). It improves blood glucose levels in adults when taken along with proper diet and regular exercise.
For more information, check out the full story on the link below: